Form 4: Director Stock Option Grant for Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc. reports a stock option grant to Director Tina Susan Nova, with vesting details and ownership information.

Summary

• Tina Susan Nova, a Director at Aurinia Pharmaceuticals Inc., was granted stock options on June 4, 2026.
• The grant includes 23,931 stock options with an exercise price of $15.67 per share.
• These options are exercisable one year from the grant date and expire on June 4, 2036.
• Following the transaction, Nova beneficially owns 23,931 shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports a standard stock option grant to a director without providing new financial performance data or strategic updates.

Positives

• Director Tina Susan Nova has been granted stock options, indicating continued alignment with shareholder interests.
• The stock options have a long expiration date (June 4, 2036), suggesting a long-term incentive.
• The options vest one year from the grant date, providing a clear performance milestone.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding future financial performance. It solely reports a stock option grant.

Industry Context

StockSavvy.ai notes that the granting of stock options to directors is a common practice in the pharmaceutical industry to incentivize long-term performance and align executive interests with those of shareholders. This type of disclosure is standard for Section 16 filings.

Stakeholder Impact

• Shareholders: The grant of options to a director can be viewed positively as it aligns director incentives with long-term company performance and shareholder value. However, the dilutive effect of future share issuance upon exercise should be considered.

Key Dates

Keywords

stock options, director compensation, Aurinia Pharmaceuticals, AUPH, insider trading, beneficial ownership, equity grant